SCHEMBL3748433

SCHEMBL3748433

CC(C)(C)[Si](OCCN1CCCN(c2ccc([N+](=O)[O-])cc2C(F)(F)F)C1=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.37
CRHR1 P34998 1/20 0.34
SMYD2 Q9NRG4 1/20 0.34
PER2 O15055 1/20 0.33
LMNA P02545 3/20 0.33
ALDH1A1 P00352 4/20 0.33
MAPK1 P28482 2/20 0.33
SLC6A9 P48067 1/20 0.33
PIM1 P11309 1/20 0.32
CDK4 P11802 1/20 0.32
CCND3 P30281 1/20 0.32
MTOR P42345 1/20 0.32
GSK3B P49841 1/20 0.32
WDR5 P61964 1/20 0.32
AR P10275 3/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 1/20 0.32
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3752623 0.89 SMYD2 (0.35) SMYD2PER2LMNAALDH1A1MAPK1
SCHEMBL3645438 0.88 ALDH1A1 (0.41) SMYD2LMNAALDH1A1MAPK1WDR5
SCHEMBL3760372 0.88 SMYD2 (0.36) SMYD2PER2MTORMAPTHTT
SCHEMBL5482922 0.84 SMYD2 (0.38) SMYD2PER2LMNAALDH1A1MAPT
SCHEMBL16502796 0.79 ALDH1A1 (0.43) HTR7CRHR1ALDH1A1SLC6A9WDR5
SCHEMBL3757378 0.78 SMYD2 (0.37) SMYD2PER2ALDH1A1MAPK1MAPT
SCHEMBL3745187 0.77 MAPT (0.37) SMYD2PER2ALDH1A1MAPTHTT
SCHEMBL27088102 0.76 KCNJ1 (0.41) LMNAALDH1A1MAPK1MAPTMEN1
SCHEMBL5482915 0.74 PER2 (0.39) SMYD2PER2HTT
SCHEMBL2993811 0.74 PER2 (0.40) SMYD2PER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX HTR7 3111/4885CRHR1 4562/4885SMYD2 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.